British health officials agreed on Sunday that controls for the epidemic could be lifted in June after a study concluded that vaccines from Pfizer and AstraZeneca provide effective protection against the variation that has emerged in India.
In recent weeks, British officials have expressed concern over the increase in cases of this variation in the United Kingdom. This can compromise the deflation plan.
According to the latest data, than 2,800 cases of Govit-19 of detected variant In India they were registered in the UK.
The British government has said the Indian variant appears to be more pervasive, but there were still uncertainties about the severity.
Jenny Harris, executive director of the UK Healthcare Organization, said on Sunday that British authorities were set to continue the final phase of the devaluation plan from June 21 if people were wary.
“People must continue to abide by all safety rules”, Jenny Harris told the BBC television channel that this variation was dominating parts of northern England and that people in this area should be vigilant.
Health Secretary Matt Hankook said the UK was “increasingly confident” that it could pursue its restructuring plans.
Reports from these two officials come after an investigation by the Public Health UK (PHE), which found that two doses of the vaccine came from Pfizer or AstraZeneca. “High security” Against symptomatic diseases found in India.
According to a study conducted from April 5 to May 16, Pfizer had the formula It is 88% effective against symptomatic disease Due to a mutation detected in India two weeks after the second dose, 93% against efficacy compared to those found in the UK.
According to the University of AstraZeneca / Oxford, experts found that the vaccine was 60% effective against the variant found in India, compared to the 66% variant found in the United Kingdom (Kent variant).